Core Viewpoint - Coya Therapeutics, Inc. has announced a public offering of common stock priced at $5.50 per share, aiming to raise capital for its clinical-stage biotechnology initiatives focused on neurodegenerative disorders [1] Company Summary - Coya Therapeutics is a clinical-stage biotechnology company that specializes in developing biologics to enhance regulatory T cell (Treg) function [1] - The company has priced an underwritten public offering of 3,636,364 shares of its common stock [1] - An option has been granted to the underwriter to purchase an additional 545,454 shares within a 30-day period [1]